Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients respond well to chemotherapy with cure rates of 80-90% and the recent finding of PD-L1 expression, an immune checkpoint, warrants the use of immunotherapy for some patients with recurrent and/or refractory HL.
|
31699300 |
2020 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Some NHL subtypes, which share certain genetic features with HL, such as alterations in chromosome 9p24.1 and expression of PD-L1, have shown promising responses in early phase trials.
|
31456438 |
2019 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting immune checkpoint pathways, such as programmed death ligand-1 (PD-L1, also known as CD274 or B7-H1) or its receptor programmed cell death-1 (PD-1) has shown improved survival for patients with numerous types of cancers, not limited to lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma.
|
30564891 |
2019 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CHL exquisite sensitivity to PD-1/PD-L1 axis inhibition relies on a particular biological background.
|
31205470 |
2019 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
|
30637917 |
2019 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Copy number alterations (CNAs) of 9p24.1 occur frequently in Hodgkin lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), primary central nervous system lymphoma, and primary testicular lymphoma, resulting in overexpression of PD-L1 and sensitivity to PD-1 blockade-based immunotherapy.
|
31471540 |
2019 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 is expressed in the cells of diffuse large B-cell lymphoma (DLBCL), one common type of malignant non-Hodgkin lymphomas.
|
29435074 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antitumor immune response of programmed cell death ligand (PD-L1) has shown clinical value not only in Hodgkin lymphoma and EBV-associated lymphomas but also in EBV-negative diffuse large B cell lymphoma (DLBCL) of non-germinal center B cell-like (non-GCB) subtype.
|
30458835 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
|
29449276 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, nodular lymphocyte-predominant HL (n = 4), lymphocyte-rich CHL (n = 6), EBV<sup>+</sup> hyperplasia (n = 8), plasmablastic lymphoma (n = 3) and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (n = 5) seldom exhibited PD-L1 in their large cells.
|
29380399 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therapeutic blockade of PD-1/PD-L1 shows promising results in Hodgkin's lymphoma (HL) and in some diffuse large B-cell lymphoma (DLBCL) patients, but biomarkers predicting such responses are still lacking.
|
30384489 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, expression levels of PD-L1 also seem to predict responses to anti-PD-1/PD-L1 approaches in patients with Hodgkin lymphoma.
|
29775689 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.
|
29698935 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expert commentary: The approval of brentuximab vedotin and PD-L1 inhibitors has ushered in a new era of targeted therapy in HL.
|
29521140 |
2018 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma.
|
28514441 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antibodies blocking the PD-1/PD-L1 axis have been shown to have substantial antitumor effects also in the treatment of Hodgkin's lymphoma (HL) relapsing after conventional chemotherapy or even autologous hematopoietic stem cell transplantation (autoHSCT).
|
28683452 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
|
28893733 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CAR-T cell-based therapies targeting CD19 can now induce durable remissions as well as prolong disease-free survival of patients with CD19 positive treatment refractory B cell malignancies and ICI-based therapies with humanized monoclonal antibodies against the T cell inhibitory receptors CTLA-4 and PD-1 as well as against the PD-1 ligand, PD-L1, can now achieve durable remissions as well as prolongation of life of a sizeable fraction of patients with melanoma and Hodgkin's lymphoma and non-small cell cancers.
|
28497159 |
2017 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In most advanced cancers, except Hodgkin lymphoma (which has high PD-L1/L2 expression) and melanoma (which has high tumor mutational burden), the objective response rate with anti-PD-1/PD-L1 monotherapy is only ~20%, and immune-related toxicities and hyperprogression can occur in a small subset of patients during PD-1/PD-L1 blockade therapy.
|
29255458 |
2017 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The available anti-PDL1 antibody clones E1L3N and SP142 were compared, and a large cohort of Hodgkin lymphomas (n=280) and B-cell lymphomas (n=619) was examined for PDL1 using E1L3N.
|
27045512 |
2016 |
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This provides a novel opportunity to inhibit the immune checkpoints and initial clinical trials utilizing antibodies that block the interaction between PD-1 and PD-L1 have demonstrated significant clinical responses in various lymphomas, including Hodgkin lymphoma.
|
26049755 |
2015 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
|
22271878 |
2012 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 is aberrantly expressed on some epithelial malignancies and Hodgkin lymphomas and may prevent effective host antitumor immunity.
|
21540239 |
2011 |
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.
|
18203952 |
2008 |
Hodgkin Disease
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|